{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T15:00:41Z","timestamp":1785078041271,"version":"3.55.0"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024370","name":"MIUR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.phrs.2026.108290","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:27:51Z","timestamp":1781206071000},"page":"108290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pharmacokinetic and pharmacodynamic rational for expanding the therapeutic landscape of psilocybin beyond depression"],"prefix":"10.1016","volume":"230","author":[{"given":"J.","family":"Mingardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Molteni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bifari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.108290_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.108080","article-title":"Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms","volume":"224","author":"Colognesi","year":"2026","journal-title":"Pharmacol. Res."},{"issue":"11","key":"10.1016\/j.phrs.2026.108290_bib2","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.tips.2025.08.012","article-title":"Emerging mechanisms of psilocybin-induced neuroplasticity","volume":"46","author":"Sonda","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2026.108290_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/WNF.0000000000000617","article-title":"Exploring Psychedelics Pharmacology: A Scoping Review Charting the Course of Psilocybin Pharmacokinetics","volume":"48","author":"Manzano-Nunez","year":"2025","journal-title":"Clin Neuropharmacol"},{"issue":"18","key":"10.1016\/j.phrs.2026.108290_bib4","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108290_bib5","article-title":"Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?","author":"Qureshi","year":"2025","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.phrs.2026.108290_bib6","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/nm.2490","article-title":"Stimulating healthy tissue regeneration by targeting the 5-HT(2)B receptor in chronic liver disease","volume":"17","author":"Ebrahimkhani","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2026.108290_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2022.105726","article-title":"Allostatic load and systemic comorbidities in psychiatric disorders","volume":"140","author":"Finlay","year":"2022","journal-title":"Psychoneuroendocrinology"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T14:08:22Z","timestamp":1785074902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826002057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":7,"alternative-id":["S1043661826002057"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108290","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic and pharmacodynamic rational for expanding the therapeutic landscape of psilocybin beyond depression","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108290"}}